These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30893101)

  • 1. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
    Perrinjaquet C; Desbaillets N; Hottinger AF
    Curr Opin Neurol; 2019 Jun; 32(3):500-510. PubMed ID: 30893101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological toxicities associated with immune-checkpoint inhibitors.
    Touat M; Talmasov D; Ricard D; Psimaras D
    Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy.
    Khalid F; Gupta R; Gor R; Gor D; Singh V; Eltoukhy H
    World J Oncol; 2023 Apr; 14(2):109-118. PubMed ID: 37188042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system injury from novel cancer immunotherapies.
    Winter SF; Vaios EJ; Dietrich J
    Curr Opin Neurol; 2020 Dec; 33(6):723-735. PubMed ID: 32941192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological Immunotoxicity from Cancer Treatment.
    Wesley SF; Haggiagi A; Thakur KT; De Jager PL
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurologic Toxicities of Immunotherapy.
    Harrison RA; Majd NK; Tummala S; de Groot JF
    Adv Exp Med Biol; 2021; 1342():417-429. PubMed ID: 34972978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurologic Toxicities of Cancer Immunotherapies: a Review.
    Harrison RA; Tummala S; de Groot J
    Curr Neurol Neurosci Rep; 2020 Jun; 20(7):27. PubMed ID: 32514633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
    Lipe DN; Shafer S
    Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
    Farina A; Villagrán-García M; Honnorat J
    Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
    Fishman JA; Hogan JI; Maus MV
    Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents.
    Bompaire F; Birzu C; Bihan K; Desestret V; Fargeot G; Farina A; Joubert B; Leclercq D; Nichelli L; Picca A; Tafani C; Weiss N; Psimaras D; Ricard D
    Rev Neurol (Paris); 2023 Jun; 179(5):405-416. PubMed ID: 37059646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Drugs and the Nervous System.
    Santomasso BD
    Continuum (Minneap Minn); 2020 Jun; 26(3):732-764. PubMed ID: 32487905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.
    Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P
    Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological complications of cancer immunotherapy (CAR T cells).
    Rubin DB; Vaitkevicius H
    J Neurol Sci; 2021 May; 424():117405. PubMed ID: 33773767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the toxicities of CAR T-cell therapy.
    Neelapu SS
    Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurologic Complications of Cancer Immunotherapy.
    Wang N
    Continuum (Minneap Minn); 2023 Dec; 29(6):1827-1843. PubMed ID: 38085900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
    Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
    J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.